# Desmoda是一種專有且獲專利的口服去氨加壓素製劑，用於治療中樞性尿崩症。

*biotech · news · 2026-02-25 · Reuters*

## Key points

- Desmoda是新獲批准用於中樞性尿崩症的口服去氨加壓素製劑。
- Desmoda解決了醫生在穩定水分和鈉水平時面臨的劑量調整挑戰。
- Eton Pharmaceuticals預計Desmoda的年度最高銷售額將達3,000萬至5,000萬美元。
- Desmoda專門用於治療精氨酸加壓素缺乏症，這是一種罕見的荷爾蒙疾病。

The drug, Desmoda, is a proprietary, patented oral formulation of desmopressin for treating central diabetes insipidus, or arginine vasopressin deficiency (AVP-D), a rare disorder in which the body lacks the hormone that regulates water balance, causing excessive urination and thirst. Sign up here. The approval helps address a long‑standing challenge in managing the condition, where doctors must carefully adjust dosing to keep water levels stable and prevent dangerous shifts in sodium, especially in children. Eton expects Desmoda to generate annual peak sales in the range of $30 million to $50 million. Reporting by Kamal Choudhury in Bengaluru; Editing by Alan Barona

**Countries:** India

[Read the full story on Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-eton-pharmas-hormonal-disorder-drug-2026-02-25/)

---

Canonical: https://newsio.io/zh-TW/n/b8d02071-c047-42d9-8fd1-328a08a765d5/desmodaetondesmoda30005000
Summarized by Newsio from Reuters. https://newsio.io/how-it-works